KR101501569B1 - Water soluble sodium silicate composition to prevent and improve alzheimer's disease and method for manufacturing thereof - Google Patents

Abstract

The present invention relates to a water-soluble silicate composition capable of preventing and improving dementia (Alzheimer's) and a method for producing the same.
The water-soluble silicate composition for prevention and treatment of dementia according to the present invention comprises
70% to 85% by weight of silicon dioxide;
8% to 12% by weight of anhydrous sodium carbonate (SODA ASH);
3% by weight to 7% by weight of Tribasic Sodium Phosphate;
2% to 6% by weight of sodium pyrophosphate;
2% by weight to 5% by weight of sodium metaphosphate,
. ≪ / RTI >

Description

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a water-soluble silicate composition for preventing and treating dementia, and a method for producing the same.

The present invention relates to a water-soluble silicate composition capable of preventing and ameliorating dementia (Alzheimer's disease) and a method for preparing the same. More specifically, the present invention relates to a water- The present invention relates to a water-soluble silicate composition capable of reducing cognitive dysfunction by decreasing aluminum level, which is a neurotoxic factor of the human body, and a method for producing a water-soluble silicate for producing such a water-soluble silicate composition.

Korean Patent No. 10-1152895 (registered May 29, 2012) discloses "Preparation of mineral water-containing silicon water and its utilization method ".

The mineral water-containing silicon water producing method is characterized in that a liquid sodium silicate (Na2O: 17 to 18%, SiO2: 36 to 38%) and a liquid sodium silicate (Na2O: 14 (Na2O: 9.0 to 10%, SiO2: 28 to 30%) and liquid sodium silicate (Na2O: 6.0 to 7.0%, SiO2: 34 to 36% (Si) water is obtained by dissolving a silicate material selected from at least one of sodium silicate and potassium silicate powder in water at a concentration of 23 to 25%, a silicate dissolution step of obtaining a silicon (Si) A cation removal process to remove single cations in the silicate dissolved in water, a dilution process to properly maintain the silicate concentration, a process to control the hydrogen ion concentration of the applied water to suit the drinking water quality conditions and to contain the mineral component A filtration process for removing foreign substances or suspended substances in the drinking water, Including at least one sub-process selected from the sterilization process to kill a bacterial infection occurs during the drinking water of the process for producing the hydrogen is characterized by obtaining the number of silicon.

However, the above invention relates to a method for producing silicate water from silicate, and there is no description about a water-soluble silicate and a method for producing the same.

Accordingly, an object of the present invention is to provide a water-soluble silicate composition capable of inhibiting cognitive dysfunction by decreasing aluminum levels, which are neurotoxic factors of the human body, by adding anhydrous sodium carbonate, sodium triphosphate, sodium pyrophosphate and sodium metaphosphate to silicon dioxide And a method for producing a water-soluble silicate for producing such a water-soluble silicate composition.

In order to achieve the above object, the present invention provides a water-soluble silicate composition for preventing and treating dementia,

70% to 85% by weight of silicon dioxide;

8% to 12% by weight of anhydrous sodium carbonate (SODA ASH);

3% by weight to 7% by weight of Tribasic Sodium Phosphate;

2% to 6% by weight of sodium pyrophosphate;

2% by weight to 5% by weight of sodium metaphosphate,

. ≪ / RTI >

The silicon dioxide is extracted from a quartz stone and is characterized by containing 60 wt% or more of an SiO ₂ component.

The present invention also provides a method for preparing a water-soluble silicate composition for preventing and treating dementia,

(1) 70 wt% to 85 wt% of silicon dioxide, 8 wt% to 12 wt% of anhydrous sodium carbonate (SODA ASH), 3 wt% to 7 wt% of tribasic sodium phosphate, 2 wt% of sodium pyrophosphate % To 6% by weight of sodium metaphosphate and 2% to 5% by weight of sodium metaphosphate;

(2) melting the mixture in a liquid state by heating the mixture at 1700 DEG C for 8 to 9 hours,

(3) naturally cooling the melt dissolved in the liquid phase, and then pulverizing the cooled coagulum into a pulverizer to a size of 325 mesh,

(4) mixing the powdered powder with water at a ratio of 1: 4 by weight, slowly heating the mixture for 6 hours or more, and then naturally cooling the cooled aqueous silicate liquid into a sterilizing vessel.

In the above, the pulverized powder is filtered by a magnet before it is mixed with water, and the naturally cooled liquid is spontaneously sedimented for 15 days or more to remove fine foreign substances precipitated in the lower layer of the liquid, Even when a silicate liquid is contained, a solid foreign substance is removed using a microfiltration device.

Thus, the water-soluble silicate composition for the prevention and treatment of dementia according to the present invention and the method for producing the same reduce the amount of aluminum, which is a neurotoxin in the body of a patient suffering from dementia (Alzheimer's disease) It is possible to inhibit or improve the cognitive function deterioration of the patient by preventing the formation of the developing toxic protein bee amyloid plaque and the tau protein tangling, and the suffering of the dementia (Alzheimer's) patient which is rapidly increasing together with the average life expectancy of the human being Of course, there is an economic effect such as reducing the economic and physical support burden of the dependent family member. It is safe because there are no side effects that occur in some medicines, and it is easy to increase and decrease according to the state of cognitive function evaluation of the patient .

The water-soluble silicate composition for prevention and treatment of dementia according to the present invention comprises

70 wt% to 85 wt% of silicon dioxide (SILICON DIOXIDE);

8% to 12% by weight of anhydrous sodium carbonate (SODA ASH);

3% by weight to 7% by weight of Tribasic Sodium Phosphate;

2% to 6% by weight of sodium pyrophosphate;

2% by weight to 5% by weight of sodium metaphosphate,

.

The silicon dioxide is extracted from the elvan and is poorly soluble. However, the alkali silicate is decomposed by chemical action such as anhydrous sodium carbonate, sodium triphosphate, sodium pyrophosphate, sodium metaphosphate and the like to produce a water-containing product and is water-soluble. The X-ray crystallization method of the elvan stone method is as follows. 65% of silicate (SiO2), 12.01% of aluminum oxide (Al2O3), 2.75% of magnesium (Mg), 2.35% of potassium (K) ) 0.275%, and manganese oxide (MnO) 0.07%. The particle shape is hexagonal porous and has an adsorption function of absorbing various components in the body by intermolecular catalysis, Strong alkaline components are neutralized with strongly acidic factors and have a strong antibacterial function. At this time, the silica extracted from the elvan is more compact than the silicon extracted from zeolite and chadol, which is a classification of granite, in the process of silicate formation, and the ion adsorption and elution functions are higher.

The anhydrous sodium carbonate (SODA ASH) is chemically reacted with the water-insoluble silicate to change the silicate into a water-soluble disodium aurate, and adjusts the amount of water soluble in the water according to its amount, , The binding and reducing action of the various ions will work, and the Si ion in the silicate binds to the anion in the body, and the Na ion of anhydrous sodium binds to various ions in the body to enhance various effects.

Tribasic Sodium Phosphate is a colorless or white crystalline solid, which is soluble in water and has a strong alkalinity. Generally, it generates pyrophosphoric acid ion and soluble salt by hydrolysis, and its dispersing and solubilizing action is active, Disperses and removes the acidification factor of the ion and inhibits ion activation.

Sodium Pyrophosphate is soluble in water and is alkaline. It has a strong function to inhibit ion activation by generating a complex with ions such as Cu2 and Al2. Therefore, it plays a role to suppress the activation of Al in the body.

The sodium metaphosphate is soluble in water and alkaline and strongly dispersible.

The method for preparing the water-soluble silicate composition for preventing and treating dementia according to the present invention is as follows.

(1) 70 wt% to 85 wt% of silicon dioxide, 8 wt% to 12 wt% of anhydrous sodium carbonate (SODA ASH), 3 wt% to 7 wt% of tribasic sodium phosphate, 2 wt% of sodium pyrophosphate % To 6% by weight of sodium metaphosphate, and 2% to 5% by weight of sodium metaphosphate.

② Heat the mixture at 1700 ℃ for 8 ~ 9 hours and melt in liquid phase.

(3) After naturally cooling the melt dissolved in the liquid phase, the cooled coagulates are pulverized into a pulverizer to a size of 325 mesh.

④ Mix the powdered powder with water at a ratio of 1: 4 by weight, slowly heat for 6 hours or more, cool it naturally, and put the water-soluble silicate liquid in a sterile container.

In the above, the pulverized powder is filtered by a magnet before it is mixed with water, and the naturally cooled liquid is spontaneously sedimented for 15 days or more to remove fine foreign substances precipitated in the lower layer of the liquid, Even when the silicate liquid is contained, the solid matter is removed using a microfiltration device.

The water-soluble silicate liquid prepared as described above is used as a medicine or as a food additive.

Then, the water-soluble silicate composition was mixed with water so as to have a silicon content of 50 mg, and the mixture was divided into three portions to be drunk.

The study included 15 patients with Alzheimer's disease, ranging in age from 56 to 80 years of age. Eight male and seven female patients were randomly selected on average, Cognitive function assessment (ADAS-C0g).

Table 1 shows the results for male subjects and Table 2 shows the results for female subjects.

division age Experiment period
week Al nmol /
mmol Crt Al μmol /
mmol Crt ADAS-
Cog / 70
01m

79
0 41.1 36.5 05 One 81.7 93.9 ↓ 12 40.3 65.4 09
03m

71
0 40.6 42.9 05 One 81.1 78.3 ↓ 12 155.4 151.9 07
05m

78
0 67.8 38.7 07 One 170.8 109.9 ↓ 12 82.7 119.1 09
07m

59
0 25.3 58.6 06 One 38.2 104.2 ↓ 12 55.8 114.7 10
09m

71
0 32.3 37.6 05 One 101.6 67.6 ↓ 12 80.6 71.1 02
11m

68
0 213.5 32.0 00 One 221.5 63.1 ↓ 12 156.4 72.7 03
13m

81
0 28.3 28.2 20 One 68.4 52.4 ↓ 12 65.0 80.1 26
15m

75
0 188.4 33.7 29 One 199.5 54.3 ↓ 12 88.6 146.3 36

division age Experiment period
week Al nmol /
mmol Crt Al μmol /
mmol Crt ADAS-
Cog / 70
02m

79
0 55.2 37.8 32 One 77.0 82.4 ↓ 12 48.3 61.7 42
04m

74
0 74.6 39.8 16 One 99.9 102.3 ↓ 12 62.0 74.2 23
06m

80
0 144.2 37.7 26 One 126.1 85.2 ↓ 12 85.6 149.7 34
08m

56
0 84.0 44.6 48 One 119.2 57.6 ↓ 12 100.6 58.7 50
10m

67
0 33.8 35.8 29 One 123.2 84.0 ↓ 12 44.5 108.4 36
12m

68
0 76.1 36.1 31 One 107.1 110.6 ↓ 12 56.4 92.0 30
14m

64
0 41.4 40.2 19 One 72.1 88.8 ↓ 12 54.9 92.5 22

As shown in Table 1 and Table 2, experimental analysis showed that 14 out of 15 subjects had improvement in cognitive function, and 1 person had lower cognitive function levels. Four of them had significantly improved grades, and 10 were no longer worse off. Experimental results showed that increasing the daily intake from 50 mg to 120 mg resulted in a higher cognitive function in the majority of patients and a 50 to 70% reduction in aluminum levels in the participants' blood samples.

Accordingly, the present invention reduces formation of toxic protein bea amyloid plaques and tau protein tangles, which is a characteristic phenomenon common to the brains of demented patients, by reducing the amount of aluminum, which is a neurotoxin in the body of dementia (Alzheimer's) patients. (Alzheimer's disease), which is rapidly growing with the aging of the average life span of a person, as well as the economic and physical support burden of the dependent family. There is an advantage of being safe because there are no side effects that appear in some medicines, and it is easy to increase and decrease according to the state of cognitive function evaluation of patients.

Claims (4)

70% to 85% by weight of silicon dioxide;
8% to 12% by weight of anhydrous sodium carbonate (SODA ASH);
3% by weight to 7% by weight of Tribasic Sodium Phosphate;
2% to 6% by weight of sodium pyrophosphate;
2% by weight to 5% by weight of sodium metaphosphate,
≪ RTI ID = 0.0 > 1, < / RTI >
delete (1) 70 wt% to 85 wt% of silicon dioxide, 8 wt% to 12 wt% of anhydrous sodium carbonate (SODA ASH), 3 wt% to 7 wt% of tribasic sodium phosphate, 2 wt% of sodium pyrophosphate % To 6% by weight of sodium metaphosphate and 2% to 5% by weight of sodium metaphosphate;
(2) melting the mixture in a liquid state by heating the mixture at 1700 DEG C for 8 to 9 hours,
(3) naturally cooling the melt dissolved in the liquid phase, and then pulverizing the cooled coagulum into a pulverizer to a size of 325 mesh,
(4) mixing the powdered powder with water in a ratio of 1: 4 by weight, and then heating the mixture for 6 hours or longer, and then naturally cooling the cooled powdered water-soluble silicate liquid into a sterilization container. ≪ / RTI >

delete